Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197 · see citing works

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735 · see citing works

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216 · see citing works

The phosphoinositide 3-kinase pathway

Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621 · see citing works

<i>PTEN</i> , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785 · see citing works

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · see citing works

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338 · see citing works

Isolation of rare circulating tumour cells in cancer patients by microchip technology

Nagrath, S., Sequist, L. V. D., Maheswaran, S., Bell, D. W., Irimia, D., Ulkus, L., Smith, M. R., Kwak, E. L., Digumarthy, S. R., Muzikansky, A., et al. (2007) · Nature · doi:10.1038/nature06385 · Cited by 3,565 · see citing works

High Frequency of Mutations of the PIK3CA Gene in Human Cancers

Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448 · see citing works

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330 · see citing works

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104 · see citing works

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083 · see citing works

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,742 · see citing works

SH2 domains recognize specific phosphopeptide sequences

Songyang, Z. (1993) · Cell · doi:10.1016/0092-8674(93)90404-e · Cited by 2,675 · see citing works

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · see citing works

Ras, PI(3)K and mTOR signalling controls tumour cell growth

Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · see citing works

Phosphatidylinositol-3-OH kinase direct target of Ras

Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954 · see citing works

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling

Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes &amp; Development · doi:10.1101/gad.1110003 · Cited by 1,911 · see citing works

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · see citing works

PI3K pathway alterations in cancer: variations on a theme

Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845 · see citing works

Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ)

Cho, H., Mu, J., Kim, J. K., Thorvaldsen, J. L., Chu, Q., Crenshaw, E. B., Kaestner, K. H., Bartolomei, M. S., Shulman, G. I., & Birnbaum, M. J. (2001) · Science · doi:10.1126/science.292.5522.1728 · Cited by 1,837 · see citing works

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803 · see citing works

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627 · see citing works

Detection of Mutations in <i>EGFR</i> in Circulating Lung-Cancer Cells

Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617 · see citing works

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555 · see citing works

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors

Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442 · see citing works

SIN1/MIP1 Maintains rictor-mTOR Complex Integrity and Regulates Akt Phosphorylation and Substrate Specificity

Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., & Su, B. (2006) · Cell · doi:10.1016/j.cell.2006.08.033 · Cited by 1,407 · see citing works

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381 · see citing works

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330 · see citing works

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

Carpten, J. D., Faber, A. L., Horn, C. L., Donoho, G. P., Briggs, S., Robbins, C. M., Hostetter, G. H., Boguslawski, S. J., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,291 · see citing works

Targeting the PI3K-Akt pathway in human cancer

Luo, J., Manning, B. D., & Cantley, L. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00248-4 · Cited by 1,290 · see citing works

The TSC1–TSC2 complex: a molecular switchboard controlling cell growth

Huang, J., & Manning, B. D. (2008) · Biochemical Journal · doi:10.1042/bj20080281 · Cited by 1,237 · see citing works

Tuberous Sclerosis Complex Gene Products, Tuberin and Hamartin, Control mTOR Signaling by Acting as a GTPase-Activating Protein Complex toward Rheb

Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C., & Blenis, J. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00506-2 · Cited by 1,211 · see citing works

Central Role for G Protein-Coupled Phosphoinositide 3-Kinase γ in Inflammation

Hirsch, E., Katanaev, V. L., Garlanda, C., Azzolino, O., Pirola, L., Silengo, L., Sozzani, S., Mantovani, A., Altruda, F., & Wymann, M. P. (2000) · Science · doi:10.1126/science.287.5455.1049 · Cited by 1,209 · see citing works

Cellular Function of Phosphoinositide 3-Kinases: Implications for Development, Immunity, Homeostasis, and Cancer

Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J. F., & Waterfield, M. D. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.615 · Cited by 1,204 · see citing works

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity

Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134 · see citing works

Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer

Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109 · see citing works

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,080 · see citing works

Insulin Activation of Rheb, a Mediator of mTOR/S6K/4E-BP Signaling, Is Inhibited by TSC1 and 2

Garami, A., Zwartkruis, F. J. T., Nobukuni, T., Joaquin, M., Roccio, M., Stocker, H., Kozma, S. C., Hafen, E., Bos, J. L., & Thomas, G. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00220-x · Cited by 1,043 · see citing works

Tenets of PTEN Tumor Suppression

Salmena, L., Carracedo, A., & Pandolfi, P. P. (2008) · Cell · doi:10.1016/j.cell.2008.04.013 · Cited by 1,033 · see citing works

Function of PI3Kγ in Thymocyte Development, T Cell Activation, and Neutrophil Migration

Sasaki, T., Irie-Sasaki, J., Jones, R. G., Oliveira-dos-Santos, A., Stanford, W. L., Bolon, B. N., Wakeham, A. C., Itié, A., Bouchard, D., Kozieradzki, I., et al. (2000) · Science · doi:10.1126/science.287.5455.1040 · Cited by 1,027 · see citing works

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964 · see citing works

Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice

Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W. P., Meek, S. E., Salpekar, A., Waterfield, M. D., et al. (2002) · Science · doi:10.1126/science.1073560 · Cited by 948 · see citing works

Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems

Podsypanina, K., Ellenson, L. H., Nemes, A., Gu, J., Tamura, M., Yamada, K. M., Cordon‐Cardo, C., Cattoretti, G., Fisher, P. E., & Parsons, R. E. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1563 · Cited by 947 · see citing works

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938 · see citing works

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

Zhang, Y., Gao, X., Saucedo, L. J., Ru, B., Edgar, B. A., & Pan, D. (2003) · Nature Cell Biology · doi:10.1038/ncb999 · Cited by 924 · see citing works

The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway

Sansal, I., & Sellers, W. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.141 · Cited by 922 · see citing works

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

Bellacosa, A., de Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837 · see citing works

Oncogenic PI3K deregulates transcription and translation

Bader, A. G., Kang, S., Zhao, L., & Vogt, P. K. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1753 · Cited by 795 · see citing works

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA.

Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., & Testa, J. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3636 · Cited by 793 · see citing works

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J. A., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1385 · Cited by 787 · see citing works

Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma.

Staal, S. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5034 · Cited by 772 · see citing works

Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase

Nobukuni, T., Joaquin, M., Roccio, M., Dann, S. G., Kim, S. Y., Gulati, P., Byfield, M. P., Backer, J., Natt, F., Bos, J. L., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506925102 · Cited by 753 · see citing works

Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation

Whitman, M., Kaplan, D., Schaffhausen, B., Cantley, L., & Roberts, T. (1985) · Nature · doi:10.1038/315239a0 · Cited by 732 · see citing works

Hypoxia regulates TSC1/2–mTOR signaling and tumor suppression through REDD1-mediated 14–3–3 shuttling

DeYoung, M. P., Horak, P., Sofer, A., Sgroi, D., & Ellisen, L. W. (2008) · Genes &amp; Development · doi:10.1101/gad.1617608 · Cited by 710 · see citing works

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

Engelman, J. A., & Janne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2248 · Cited by 706 · see citing works

Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis

Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S., Zhang, J., Signoretti, S., Loda, M. F., Roberts, T. M., et al. (2008) · Nature · doi:10.1038/nature07091 · Cited by 691 · see citing works

Pten Dose Dictates Cancer Progression in the Prostate

Trotman, L. C., Niki, M., Dotan, Z., Koutcher, J. A., Cristofano, A. D., Xiao, A., Khoo, A. S. B., Roy‐Burman, P., Greenberg, N. M., Dyke, T. V., et al. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000059 · Cited by 677 · see citing works

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., SEELIG, S. A., & Arteaga, C. L. (2002) · PubMed · Cited by 611 · see citing works

Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ

Pacold, M. E., Suire, S., Perišić, O., Lara‐González, S., Davis, C. T., Walker, E. H., Hawkins, P. T., Stephens, L., Eccleston, J. F., & Williams, R. L. (2000) · Cell · doi:10.1016/s0092-8674(00)00196-3 · Cited by 603 · see citing works

Mutations in a signalling pathway

Parsons, D. W., Wang, T., Samuels, Y., Bardelli, A., Cummins, J. M., Wood, L. D., Silliman, N., Ptak, J., Szabo, S., Willson, J. K. V., et al. (2005) · Nature · doi:10.1038/436792a · Cited by 599 · see citing works

Class I PI3K in oncogenic cellular transformation

Zhao, L., & Vogt, P. K. (2008) · Oncogene · doi:10.1038/onc.2008.244 · Cited by 598 · see citing works

PTEN: a tumour suppressor that functions as a phospholipid phosphatase

Maehama, T. (1999) · Trends in Cell Biology · doi:10.1016/s0962-8924(99)01519-6 · Cited by 591 · see citing works

Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice

Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E. L., Stamp, G., Alitalo, K. K., & Downward, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.051 · Cited by 589 · see citing works

Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial–mesenchymal transition

Irie, H. Y., Pearline, R. V., Grueneberg, D. A., Hsia, M., Ravichandran, P., Kothari, N. H., Natesan, S., & Brugge, J. S. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505087 · Cited by 588 · see citing works

The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations

Huang, C., Mandelker, D. L., Schmidt‐Kittler, O., Samuels, Y., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., Gabelli, S. B., & Amzel, L. M. (2007) · Science · doi:10.1126/science.1150799 · Cited by 564 · see citing works

A Family with Severe Insulin Resistance and Diabetes Due to a Mutation in AKT2

George, S., Rochford, J. J., Wolfrum, C., Gray, S. L., Schinner, S., Wilson, J. C., Soos, M. A., Murgatroyd, P. R., Williams, R. M., Acerini, C. L., et al. (2004) · Science · doi:10.1126/science.1096706 · Cited by 559 · see citing works

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., & Arteaga, C. L. (2001) · PubMed · Cited by 548 · see citing works

PTEN-deficient cancers depend on PIK3CB

Wee, S., Wiederschain, D., Maira, S.-M., Loo, A. T., Miller, C., deBeaumont, R. S., Stegmeier, F. P., Yao, Y.-M., & Christoph Lengauer, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802655105 · Cited by 545 · see citing works

hVps34 Is a Nutrient-regulated Lipid Kinase Required for Activation of p70 S6 Kinase

Byfield, M. P., Murray, J. T., & Backer, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507201200 · Cited by 526 · see citing works

AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer

Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.012 · Cited by 524 · see citing works

Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration

Graupera, M., Guillermet‐Guibert, J., Foukas, L. C., Phng, L., Cain, R. J., Salpekar, A., Pearce, W. P., Meek, S. E., Millán, J., Cutillas, P. R., et al. (2008) · Nature · doi:10.1038/nature06892 · Cited by 521 · see citing works

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

Guix, M., Faber, A. C., Wang, S. E., Olivares, M. G., Song, Y., Qu, S., Rinehart, C., Seidel, B., Yee, D., Arteaga, C. L., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34588 · Cited by 519 · see citing works

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235

Eichhorn, P. J. A., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R. L., Valero, V., Seoane, J., Bernards, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1740 · Cited by 499 · see citing works

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

Engelman, J. A., Janne, P. A., Mermel, C. H., Pearlberg, J., Mukohara, T., Fleet, C., Cichowski, K. M., Johnson, B. E., & Cantley, L. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409773102 · Cited by 494 · see citing works

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

Garcı́a-Echeverrı́a, C., & Sellers, W. R. (2008) · Oncogene · doi:10.1038/onc.2008.246 · Cited by 474 · see citing works

PI3Kγ Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects

Patrucco, E., Notte, A., Barberis, L., Selvetella, G., Maffei, A., Brancaccio, M., Marengo, S., Russo, G., Azzolino, O., Rybalkin, S. D., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.017 · Cited by 465 · see citing works

mTOR and cancer therapy

Easton, J. B., & Houghton, P. J. (2006) · Oncogene · doi:10.1038/sj.onc.1209886 · Cited by 460 · see citing works

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

Engelman, J. A., Mukohara, T., Zejnullahu, K., Lifshits, E., Borras, A. M., Gale, C.-M., Naumov, G. N., Yeap, B. Y., Jarrell, E., Sun, J., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28656 · Cited by 457 · see citing works

The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.

Philp, A., Campbell, I., Leet, C. S. F., Vincan, E., Rockman, S., Whitehead, R. H., Thomas, R. J., & Phillips, W. A. (2001) · PubMed · Cited by 455 · see citing works

Signalling by PI3K isoforms: insights from gene-targeted mice

Vanhaesebroeck, B., Ali, K., Bilancio, A., Geering, B., & Foukas, L. C. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.02.008 · Cited by 450 · see citing works

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

Bianco, R., Shin, I., Ritter, C. A., Yakes, F. M., Basso, A., Rosen, N. X., Tsurutani, J., Dennis, P. A., Mills, G. B., & Arteaga, C. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206388 · Cited by 449 · see citing works

A Crucial Role for the p110δ Subunit of Phosphatidylinositol 3-Kinase in B Cell Development and Activation

Clayton, E., Bardi, G., Bell, S. E., Chantry, D., Downes, C. P., Gray, A., Humphries, L. A., Rawlings, D. J., Reynolds, H., Vigorito, E., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020805 · Cited by 446 · see citing works

Proliferative Defect and Embryonic Lethality in Mice Homozygous for a Deletion in the p110α Subunit of Phosphoinositide 3-Kinase

Bi, L., Okabe, I., Bernard, D. J., Wynshaw-Boris, A. J., & Nussbaum, R. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.10963 · Cited by 444 · see citing works

Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

Zhao, L., & Vogt, P. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712169105 · Cited by 438 · see citing works

PIK3CA as an oncogene in cervical cancer

Ma, Y.-Y., Wei, S., Lin, Y., Lung, J.-C., Chang, T.-C., Whang‐Peng, J., Liu, J. M., Yang, D.-M., Yang, W. K., & Shen, C. (2000) · Oncogene · doi:10.1038/sj.onc.1203597 · Cited by 434 · see citing works

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

Hideshima, T., Catley, L. P., Yasui, H., Ishitsuka, K., Raje, N. S., Mitsiades, C. S., Podar, K., Munshi, N. C., Chauhan, D., Richardson, P. G. G., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3434 · Cited by 423 · see citing works

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

She, Q., Solit, D. B., Ye, Q., O'Reilly, K. E., Lobo, J. M., & Rosen, N. X. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.006 · Cited by 416 · see citing works

Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit

Miled, N., Yan, Y., Hon, W., Perišić, O., Zvelebil, M., Inbar, Y., Schneidman‐Duhovny, D., Wolfson, H. J., Backer, J., & Williams, R. L. (2007) · Science · doi:10.1126/science.1135394 · Cited by 410 · see citing works

Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.

Kondapaka, S. B., Singh, S. S., Dasmahapatra, G. P., Sausville, E. A., & Roy, K. K. (2003) · PubMed · Cited by 402 · see citing works

Essential, Nonredundant Role for the Phosphoinositide 3-Kinase p110δ in Signaling by the B-Cell Receptor Complex

Jou, S., Carpino, N., Takahashi, Y., Piekorz, R. P., Chao, J.-R., Carpino, N., Wang, D., & Ihle, J. N. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.24.8580-8591.2002 · Cited by 357 · see citing works

Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases

Raynaud, F. I., Eccles, S. A., Clarke, P. A., Hayes, A., Nutley, B. P., Alix, S., Henley, A. T., Di-Stefano, F., Ahmad, Z., Guillard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4615 · Cited by 350 · see citing works

Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas

Ruggeri, B., Huang, L., Wood, M., Cheng, J. Q., & Testa, J. R. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199802)21:2 · Cited by 329 · see citing works

PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer

Ogino, S., Nosho, K., Kirkner, G. J., Shima, K., Irahara, N., Kure, S., Chan, A. T., Engelman, J. A., Kraft, P., Cantley, L. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6544 · Cited by 323 · see citing works

Early embryonic lethality in mice deficient in the p110β catalytic subunit of PI 3-kinase

Bi, L., Okabe, I., Bernard, D. J., & Nussbaum, R. L. (2002) · Mammalian Genome · doi:10.1007/bf02684023 · Cited by 317 · see citing works

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

Ihle, N. T., Williams, R. R., Chow, S., Chew, W. M., Berggren, M. I., Paine-Murrieta, G. D., Minion, D. J., Halter, R. J., Wipf, P., Abraham, R. T., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.763.3.7 · Cited by 317 · see citing works

Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Rhodes, N., Heerding, D. A., Duckett, D. R., Eberwein, D. J., Knick, V. B., Lansing, T. J., McConnell, R. T., Gilmer, T. M., Zhang, S., Robell, K. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5783 · Cited by 298 · see citing works

Biomarker Changes During Neoadjuvant Anastrozole, Tamoxifen, or the Combination: Influence of Hormonal Status and HER-2 in Breast Cancer—A Study from the IMPACT Trialists

Dowsett, M., Ebbs, S. R., Dixon, J. M., Skene, A. I., Griffith, C. D. M., Boeddinghaus, I., Salter, J., DETRE, S. I., Hills, M., Ashley, S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.559 · Cited by 287 · see citing works

Acquired resistance to tyrosine kinase inhibitors during cancer therapy

Engelman, J. A., & Settleman, J. E. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.004 · Cited by 282 · see citing works

Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKCλ/ζ

Taniguchi, C. M., Kondo, T., Sajan, M. P., Luo, J., Bronson, R. T., Asano, T., Farese, R. V., Cantley, L. C., & Kahn, C. R. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.04.005 · Cited by 282 · see citing works

A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity

Garlich, J. R., De, P. K. R., Dey, N., Su, J. D., Peng, X., Miller, A., Murali, R., Lu, Y., Mills, G. B., Kundra, V., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-0669 · Cited by 280 · see citing works

Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance

Ihle, N. T., Lemos, R., Wipf, P., Yacoub, A., Mitchell, C., Siwak, D. R., Mills, G. B., Dent, P., Kirkpatrick, D. L., & Powis, G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6656 · Cited by 275 · see citing works

A novel AKT3 mutation in melanoma tumours and cell lines

Davies, M. A., Stemke‐Hale, K., Tellez, C. S., Calderone, T. L., Deng, W., Prieto, V. G., Lazar, A. J., Gershenwald, J. E., & Mills, G. B. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604637 · Cited by 273 · see citing works

A New Mutational aktivation in the PI3K Pathway

Brugge, J. S., Hung, M., & Mills, G. B. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.014 · Cited by 264 · see citing works

Phosphoinositide 3‐kinases in cell migration

Cain, R. J., & Ridley, A. J. (2008) · Biology of the Cell · doi:10.1042/bc20080079 · Cited by 261 · see citing works

Heterodimeric Phosphoinositide 3-Kinase Consisting of p85 and p110β Is Synergistically Activated by the βγ Subunits of G Proteins and Phosphotyrosyl Peptide

Kurosu, H., Maehama, T., Okada, T., Yamamoto, T., Hoshino, S.-I., Fukui, Y., Ui, M., Hazeki, O., & Katada, T. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24252 · Cited by 260 · see citing works

The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer Therapy

Abraham, R. T., & Gibbons, J. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2798 · Cited by 244 · see citing works

Essential role for the p110 isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia

Sujobert, P. (2005) · Blood · doi:10.1182/blood-2004-08-3225 · Cited by 243 · see citing works

Akt1 Ablation Inhibits, whereas Akt2 Ablation Accelerates, the Development of Mammary Adenocarcinomas in Mouse Mammary Tumor Virus (MMTV)-ErbB2/Neu and MMTV-Polyoma Middle T Transgenic Mice

Maroulakou, I. G., Oemler, W., Naber, S. P., & Tsichlis, P. N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3782 · Cited by 237 · see citing works

Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis

Shah, N. P., Kasap, C., Weier, C. A., Balbas, M., Nicoll, J. M., Bleickardt, E. W., Nicaise, C., & Sawyers, C. L. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.11.001 · Cited by 231 · see citing works

Signaling network of the Btk family kinases

Qiu, Y., & Kung, H.-J. (2000) · Oncogene · doi:10.1038/sj.onc.1203958 · Cited by 225 · see citing works

Non-parametric quantification of protein lysate arrays

Hu, J., He, X., Baggerly, K., Coombes, K. R., Hennessy, B. T., & Mills, G. B. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm283 · Cited by 224 · see citing works

Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway.

Massion, P. P., Kuo, W.-L., Stokoe, D., Olshen, A. B., TRESELER, P. A., Chin, K., Chen, C., Polikoff, D., Jain, A. N., Pinkel, D., et al. (2002) · PubMed · Cited by 224 · see citing works

Perifosine: Update on a novel Akt inhibitor

Gills, J. J., & Dennis, P. A. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0016-4 · Cited by 221 · see citing works

United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling

Manning, B. D., & Cantley, L. C. (2003) · Biochemical Society Transactions · doi:10.1042/bst0310573 · Cited by 211 · see citing works

Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non–Small Cell Lung Cancer Cell Line

Ogino, A., Kitao, H., Hirano, S., Uchida, A., Ishiai, M., Kozuki, T., Takigawa, N., Takata, M., Kiura, K., & Tanimoto, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0681 · Cited by 193 · see citing works

A Dual Phosphoinositide-3-Kinase α/mTOR Inhibitor Cooperates with Blockade of Epidermal Growth Factor Receptor in PTEN -Mutant Glioma

Fan, Q.-W., Cheng, C. K., Nicolaides, T. P., Hackett, C. S., Knight, Z. A., Shokat, K. M., & Weiss, W. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2154 · Cited by 193 · see citing works

Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung

Malanga, D., Scrima, M., Marco, C. D., Fabiani, F., Rosa, N. D., Gisi, S. D., Malara, N., Savino, R., Rocco, G., Chiappetta, G., et al. (2008) · Cell Cycle · doi:10.4161/cc.7.5.5485 · Cited by 190 · see citing works

Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma

Byun, D., Cho, K., Ryu, B., Lee, M., Park, J., Chae, K. S., Kim, H. J., & Chi, S. (2003) · International Journal of Cancer · doi:10.1002/ijc.10962 · Cited by 184 · see citing works

Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin

Rini, B. I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4719 · Cited by 183 · see citing works

Regulation of the p85/p110α Phosphatidylinositol 3′-Kinase

Yu, J., Wjasow, C., & Backer, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30199 · Cited by 183 · see citing works

Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis

Rychahou, P. G., Kang, J., Gulhati, P., Doan, H. Q., Chen, L. A., Xiao, S., Chung, D. H., & Evers, B. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810715105 · Cited by 177 · see citing works

Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging

Schnell, C., Stauffer, F., ALLEGRINI, P. R., O’Reilly, T., McSheehy, P. M. J., Dartois, C., Stumm, M., Cozens, R. M., Littlewood-Evans, A. J., Garcia-Echeverria, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1044 · Cited by 175 · see citing works

Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition

Han, E. K.-H., Leverson, J. D., McGonigal, T. P., Shah, O. J., Woods, K. W., Hunter, T. R., Giranda, V. L., & Luo, Y. (2007) · Oncogene · doi:10.1038/sj.onc.1210343 · Cited by 169 · see citing works

Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a Novel Inhibitor of AKT Kinase

Heerding, D. A., Rhodes, N., Leber, J. D., Clark, T. J., Keenan, R. M., LaFrance, L. V., Li, M., Safonov, I. G., Takata, D. T., Venslavsky, J. W., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8004527 · Cited by 167 · see citing works

High-Resolution Melting Analysis for Rapid Detection ofKRAS, BRAF,andPIK3CAGene Mutations in Colorectal Cancer

Simi, L., Pratesi, N., Vignoli, M., Sestini, R., Cianchi, F., Valanzano, R., Nobili, S., Mini, E., Pazzagli, M., & Orlando, C. (2008) · American Journal of Clinical Pathology · doi:10.1309/lwdy1axhxuulnvhq · Cited by 164 · see citing works

A selective inhibitor of the p110δ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16

Billottet, C., Grandage, V., Gale, R. E., Quattropani, A., Rommel, C., Vanhaesebroeck, B., & Khwaja, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209670 · Cited by 153 · see citing works

Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma

Woenckhaus, J., Steger, K., Werner, E., Fenic, I., Gamerdinger, U., Dreyer, T., & Stahl, U. (2002) · The Journal of Pathology · doi:10.1002/path.1207 · Cited by 152 · see citing works

Mechanism ofcyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: Analysis of allele-specific expression

Hosokawa, Y., & Arnold, A. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199805)22:1 · Cited by 147 · see citing works

Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.

Sawyer, C., Sturge, J., Bennett, D. C., O’Hare, M. J., Allen, W. E., Bain, J., Jones, G. E., & Vanhaesebroeck, B. (2003) · PubMed · Cited by 147 · see citing works

BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis?

Velho, S., Moutinho, C., Cirnes, L., Albuquerque, C. M., Hamelin, R., Schmitt, F. C., Carneiro, F., Oliveíra, C., & Seruca, R. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-255 · Cited by 142 · see citing works

Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias

Kim, M. S., Jeong, E. G., Yoo, N. J., & Lee, S. H. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604212 · Cited by 140 · see citing works

Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia.

Miller, C. T., Moy, J. R., Lin, L., Schipper, M. J., Normolle, D. P., Brenner, D. E., Iannettoni, M. D., Orringer, M. B., & Beer, D. G. (2003) · PubMed · Cited by 135 · see citing works

The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures

Howes, A. L., Chiang, G. G., Lang, E. S., Ho, C., Powis, G., Vuori, K., & Abraham, R. T. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0698 · Cited by 135 · see citing works

mTOR inhibitors in the treatment of cancer

Fasolo, A., & Sessa, C. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.11.1717 · Cited by 131 · see citing works

A Function for Phosphatidylinositol 3-Kinase β (p85α-p110β) in Fibroblasts during Mitogenesis: Requirement for Insulin- and Lysophosphatidic Acid-Mediated Signal Transduction

Roche, S., Downward, J., Raynal, P., & Courtneidge, S. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.12.7119 · Cited by 128 · see citing works

Pharmacodynamic Markers of Perifosine Efficacy

Hennessy, B. T., Lu, Y., Poradosu, E., Yu, Q., Yu, S., Hall, H. S., Carey, M. S., Ravoori, M. K., Gonzalez-Angulo, A. M., Birch, R., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0760 · Cited by 127 · see citing works

Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment.

Stein, R. C. (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080237 · Cited by 127 · see citing works

A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition

Torbett, N. E., Luna-Moran, A., Knight, Z. A., Houk, A. R., Moasser, M. M., Weiss, W. A., Shokat, K. M., & Stokoe, D. (2008) · Biochemical Journal · doi:10.1042/bj20080639 · Cited by 124 · see citing works

Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma

Dunlap, J. B., Le, C., Shukla, A., Patterson, J., Presnell, A., Heinrich, M. C., Corless, C. L., & Troxell, M. L. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0406-1 · Cited by 121 · see citing works

Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt

Yamasaki, F., Johansen, M. J., Zhang, D., Krishnamurthy, S., Felix, E. A., Bartholomeusz, C., Aguilar, R. J., Kurisu, K., Mills, G. B., Hortobágyi, G. N., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3020 · Cited by 119 · see citing works

Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase

Carson, J. D., Aller, G. V., Lehr, R. V., Sinnamon, R. H., Kirkpatrick, R. B., Auger, K. R., Dhanak, D., Copeland, R. A., Gontarek, R. R., Tummino, P. J., et al. (2007) · Biochemical Journal · doi:10.1042/bj20070681 · Cited by 116 · see citing works

Short Preoperative Treatment With Erlotinib Inhibits Tumor Cell Proliferation in Hormone Receptor–Positive Breast Cancers

Guix, M., Granja, N. D. M., Meszoely, I. M., Adkins, T. B., Wieman, B. M., Frierson, K. E., Sanchez, V., Sanders, M. E., Grau, A. M., Mayer, I. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5939 · Cited by 111 · see citing works

Class 1A PI3K regulates vessel integrity during development and tumorigenesis

Yuan, T. L., Choi, H. S., Matsui, A., Benes, C. H., Lifshits, E., Luo, J., Frangioni, J. V., & Cantley, L. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804123105 · Cited by 99 · see citing works

mTOR Pathway and mTOR Inhibitors as Agents for Cancer Therapy

Baldo, P., Cecco, S., Giacomin, E., Lazzarini, R., Rós, B. D. T., & Marastoni, S. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908786733513 · Cited by 97 · see citing works

Discovery of Drug-Resistant and Drug-Sensitizing Mutations in the Oncogenic PI3K Isoform p110α

Zunder, E. R., Knight, Z. A., Houseman, B. T., Apsel, B., & Shokat, K. M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.014 · Cited by 95 · see citing works

Mechanism of Constitutive Phosphoinositide 3-Kinase Activation by Oncogenic Mutants of the p85 Regulatory Subunit

Shekar, S. C., Wu, H., Fu, Z., Yip, S.-C., Nagajyothi, Cahill, S. M., Girvin, M. E., & Backer, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506005200 · Cited by 85 · see citing works

Phosphoinositide 3-OH kinase p85α and p110β are essential for androgen receptor transactivation and tumor progression in prostate cancers

Zhu, Q., Youn, H., Tang, J., Tawfik, O. W., Dennis, K. L., Terranova, P. F., Du, J., Raynal, P., Thrasher, J. B., & Li, B. (2008) · Oncogene · doi:10.1038/onc.2008.91 · Cited by 80 · see citing works

Phosphatidylinositol 3-Kinase Mediates Bronchioalveolar Stem Cell Expansion in Mouse Models of Oncogenic K-ras-Induced Lung Cancer

Yang, Y., Iwanaga, K., Raso, M. G., Wislez, M., Hanna, A. E., Wieder, E., Molldrem, J. J., Wistuba, I. I., Powis, G., DeMayo, F. J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002220 · Cited by 77 · see citing works

Targeting the PI3K p110α Isoform Inhibits Medulloblastoma Proliferation, Chemoresistance, and Migration

Stücklin, A. G., Fattet, S., Fischer, B. E., Shalaby, T., Jackson, S. P., Schoenwaelder, S. M., Grotzer, M. A., Delattre, O., & Arcaro, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0385 · Cited by 77 · see citing works

Targeting the Phosphoinositide 3-Kinase Isoform p110δ Impairs Growth and Survival in Neuroblastoma Cells

Boller, D., Schramm, A. R., Doepfner, K. T., Shalaby, T., von Bueren, A. O., Eggert, A., Grotzer, M. A., & Arcaro, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0737 · Cited by 74 · see citing works

Inhibition of Class I Phosphoinositide 3-Kinase Activity Impairs Proliferation and Triggers Apoptosis in Acute Promyelocytic Leukemia without Affecting Atra-Induced Differentiation

Billottet, C., Banerjee, L., Vanhaesebroeck, B., & Khwaja, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2608 · Cited by 56 · see citing works

Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry

Cutillas, P. R., Khwaja, A., Graupera, M., Pearce, W. P., Gharbi, S., Waterfield, M. D., & Vanhaesebroeck, B. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602101103 · Cited by 41 · see citing works

Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity

Ihle, N. T., Lemos, R., Schwartz, D. A., Oh, J., Halter, R. J., Wipf, P., Kirkpatrick, L., & Powis, G. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0714 · Cited by 29 · see citing works

Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies

Flinn, I. W., Byrd, J. C., Furman, R. R., Brown, J. R., Lin, T. S., Bello, C., Giese, N. A., & Yu, A. S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3543 · Cited by 18 · see citing works

Cell Signaling by Receptor Tyrosine Kinases

Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929 · see citing works

The molecular biology of head and neck cancer

Leemans, C. R., Braakhuis, B. J. M., & Brakenhoff, R. H. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2982 · Cited by 2,586 · see citing works

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138 · see citing works

Targeting PI3K/Akt signal transduction for cancer therapy

He, Y., Sun, M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,996 · see citing works

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

Hidalgo, M. M., Amant, F. C., Biankin, A. V., Budínská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,759 · see citing works

PI3K and cancer: lessons, challenges and opportunities

Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,716 · see citing works

Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis

Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., et al. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.001 · Cited by 1,537 · see citing works

Targeting cancer metabolism: a therapeutic window opens

Heiden, M. G. V. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3504 · Cited by 1,409 · see citing works

Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming

Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.016 · Cited by 1,395 · see citing works

PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting

Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3860 · Cited by 1,365 · see citing works

The ErbB/HER family of protein-tyrosine kinases and cancer

Roskoski, R. J. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,365 · see citing works

Nanomaterials for Theranostics: Recent Advances and Future Challenges

Lim, E., Kim, T., Paik, S., Haam, S., Huh, Y., & Lee, K. (2014) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,236 · see citing works

Imaging biomarker roadmap for cancer studies

O'Connor, J. P. B., Aboagye, E. O., Adams, J. E., Aerts, H. J. W. L., Barrington, S. F., Beer, A. J., Boellaard, R., Bohndiek, S. E., Brady, M., Brown, G., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.162 · Cited by 1,091 · see citing works

Targeting metabolic transformation for cancer therapy

Tennant, D. A., Durán, R. V., & Gottlieb, E. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2817 · Cited by 1,057 · see citing works

Targeting the PI3K pathway in cancer: are we making headway?

Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033 · see citing works

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048 · see citing works

Molecular mechanisms of cancer development in obesity

Khandekar, M. J., Cohen, P., & Spiegelman, B. M. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3174 · Cited by 906 · see citing works

Novel mutations target distinct subgroups of medulloblastoma

Robinson, G. W., Parker, M. D., Kranenburg, T. A., Lu, C., Chen, X. '., Ding, L., Phoenix, T. N., Hedlund, E., Wei, L., Zhu, X., et al. (2012) · Nature · doi:10.1038/nature11213 · Cited by 835 · see citing works

The PI3K/AKT Pathway as a Target for Cancer Treatment

Mayer, I. A., & Arteaga, C. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-062913-051343 · Cited by 826 · see citing works

Translational control in cancer

Silvera, D., Formenti, S. C., & Schneider, R. J. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2824 · Cited by 820 · see citing works

Autophagy as a target for anticancer therapy

Jankú, F., McConkey, D. J., Hong, D. S., & Kurzrock, R. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.71 · Cited by 803 · see citing works

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

Polivka, J., & Janku, F. (2014) · Pharmacology &amp; Therapeutics · doi:10.1016/j.pharmthera.2013.12.004 · Cited by 765 · see citing works

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

Luca, A. D., Maiello, M. R., D’Alessio, A., Pergameno, M., & Normanno, N. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.639361 · Cited by 739 · see citing works

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

Lannutti, B. J., Meadows, S. A., Herman, S. E. M., Kashishian, A., Steiner, B. H., Johnson, A. J., Byrd, J. C., Tyner, J. W., Loriaux, M., Deininger, M., et al. (2010) · Blood · doi:10.1182/blood-2010-03-275305 · Cited by 726 · see citing works

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.

(2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.05.01 · Cited by 716 · see citing works

Metabolic targets for cancer therapy

Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 705 · see citing works

The interplay between cell signalling and the mevalonate pathway in cancer

Mullen, P., Yu, R., Longo, J., Archer, M. C., & Penn, L. Z. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.76 · Cited by 697 · see citing works

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Bendell, J. C., Rodon, J. A., Burris, H. A., de Jonge, M. J. A., Verweij, J., Birle, D. C., Demanse, D., Buck, S. S. D., Ru, Q. C., Peters, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 687 · see citing works

The PI3K/AKT/mTOR interactive pathway

Ersahin, T., Tuncbag, N., & Cetin-Atalay, R. (2015) · Molecular BioSystems · doi:10.1039/c5mb00101c · Cited by 683 · see citing works

The relation between PI3K/AKT signalling pathway and cancer

Noorolyai, S., Shajari, N., Baghbani, E., Sadreddini, S., & Baradaran, B. (2019) · Gene · doi:10.1016/j.gene.2019.02.076 · Cited by 661 · see citing works

Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy

Tewari, D., Patni, P., Bishayee, A., Sah, A. N., & Bishayee, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.008 · Cited by 655 · see citing works

Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage

Angulo, I., Vadas, O., Garçon, F., Banham-Hall, E., Plagnol, V., Leahy, T. R., Baxendale, H., Coulter, T. I., Curtis, J. W., Wu, C., et al. (2013) · Science · doi:10.1126/science.1243292 · Cited by 639 · see citing works

Biological response of cancer cells to radiation treatment

Baskar, R., Dai, J., Nei, W. L., Yeo, R., & Yeoh, K. (2014) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2014.00024 · Cited by 638 · see citing works

PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives

Asati, V., Mahapatra, D. K., & Bharti, S. K. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.01.012 · Cited by 618 · see citing works

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588 · see citing works

Targeted therapy in patients with PIK3CA-related overgrowth syndrome

Venot, Q., Blanc, T., Hadj-Rabia, S., Berteloot, L., Ladraa, S., Huyen, J. D. V., Blanc, E., Johnson, S. C., Hoguin, C., Boccara, O., et al. (2018) · Nature · doi:10.1038/s41586-018-0217-9 · Cited by 588 · see citing works

The Mitochondrial Permeability Transition Pore: Channel Formation by F-ATP Synthase, Integration in Signal Transduction, and Role in Pathophysiology

Bernardi, P., Rasola, A., Forte, M. A., & Lippe, G. (2015) · Physiological Reviews · doi:10.1152/physrev.00001.2015 · Cited by 586 · see citing works

Regulation of the pentose phosphate pathway in cancer

Jiang, P., Du, W., & Wu, M. (2014) · Protein & Cell · doi:10.1007/s13238-014-0082-8 · Cited by 568 · see citing works

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

Li, X., Wu, C., Chen, N., Gu, H., Yen, A., Cao, L., Wang, E., & Wang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7961 · Cited by 545 · see citing works

Targeting the PI3K signaling pathway in cancer

Wong, K.-K., Engelman, J. A., & Cantley, L. C. (2010) · Current Opinion in Genetics &amp; Development · doi:10.1016/j.gde.2009.11.002 · Cited by 543 · see citing works

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

Yap, T. A., Li, Y., Patnaik, A., Fearen, I., Olmos, D., Papadopoulos, K. P., Baird, R. D., Delgado, L., Taylor, A. B., Lupinacci, L. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5263 · Cited by 540 · see citing works

FOXO Signaling Pathways as Therapeutic Targets in Cancer

Farhan, M., Wang, H., Gaur, U., Little, P. J., Xu, J., & Zheng, W. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.20052 · Cited by 538 · see citing works

Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade

Ferrere, G., Tidjani Alou, M., Liu, P., Goubet, A.-G., Fidelle, M., Kepp, O., Durand, S., Iebba, V., Fluckiger, A., Daillère, R., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.145207 · Cited by 533 · see citing works

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Maira, S.-M., Pecchi, S., Huang, A., Burger, M. T., Knapp, M. S., Sterker, D., Schnell, C., Guthy, D. A., Nagel, T., Wiesmann, M., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0474 · Cited by 533 · see citing works

Cell motility in cancer invasion and metastasis: insights from simple model organisms

Stuelten, C. H., Parent, C. A., & Montell, D. J. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2018.15 · Cited by 510 · see citing works

Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma

Perry, J. A., Kiezun, A., Tonzi, P., Van Allen, E. M., Carter, S. L., Baca, S. C., Cowley, G. S., Bhatt, A. S., Rheinbay, E., Pedamallu, C. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419260111 · Cited by 481 · see citing works

The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade

Weigelt, B., Baehner, F. L., & Reis-Filho, J. S. (2009) · The Journal of Pathology · doi:10.1002/path.2648 · Cited by 482 · see citing works

Angiogenesis Inhibitors: Current Strategies and Future Prospects

Cook, K. M., & Figg, W. D. (2010) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20075 · Cited by 478 · see citing works

The mutational landscape of adenoid cystic carcinoma

Ho, A. S., Kannan, K. S., Roy, D. M., Morris, L. G. T., Ganly, I., Katabi, N., Ramaswami, D., Walsh, L. A., Eng, S., Huse, J. T., et al. (2013) · Nature Genetics · doi:10.1038/ng.2643 · Cited by 466 · see citing works

Strategies for optimizing the response of cancer and normal tissues to radiation

Moding, E. J., Kastan, M. B., & Kirsch, D. G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4003 · Cited by 461 · see citing works

Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer

Fumarola, C., Bonelli, M. A., Petronini, P. G., & Alfieri, R. R. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.05.011 · Cited by 463 · see citing works

PI3K signaling in cancer: beyond AKT

Lien, E. C., Dibble, C. C., & Toker, A. (2017) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.02.007 · Cited by 446 · see citing works

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations

Jankú, F., Wheler, J. J., Westin, S. N., Moulder, S., Naing, A., Tsimberidou, A. M., Fu, S., Falchook, G. S., Hong, D. S., Garrido‐Laguna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1196 · Cited by 448 · see citing works

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

Burris, H. A. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2043-3 · Cited by 446 · see citing works

mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases

Palmieri, M., Pal, R., Nelvagal, H. R., Lotfi, P., Stinnett, G. R., Seymour, M. L., Chaudhury, A., Bajaj, L., Bondar, V. V., Bremner, L., et al. (2017) · Nature Communications · doi:10.1038/ncomms14338 · Cited by 430 · see citing works

MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches

Kufe, D. W. (2012) · Oncogene · doi:10.1038/onc.2012.158 · Cited by 440 · see citing works

mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling

Julien, L.-A., Carriere, A., Moreau, J., & Roux, P. P. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00601-09 · Cited by 433 · see citing works

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer

Bosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., Tao, J. J., Spratt, D. E., Viola, N. T., Castel, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4442 · Cited by 432 · see citing works

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

Shimizu, T., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Smith, L. S., Gunn, S., Smetzer, L., Mays, T. A., Kaiser, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2381 · Cited by 431 · see citing works

Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience

Sholl, L. M., Aisner, D. L., Varella-Garcia, M., Berry, L. D., Dias-Santagata, D., Wistuba, I. I., Chen, H., Fujimoto, J., Kugler, K., Franklin, W. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000516 · Cited by 430 · see citing works

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

Wander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44145 · Cited by 427 · see citing works

MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma

Fang, Y., Xue, J., Shen, Q., Chen, J., & Tian, L. (2012) · Hepatology · doi:10.1002/hep.25576 · Cited by 425 · see citing works

FOXO Transcription Factors: Their Clinical Significance and Regulation

Wang, Y., Zhou, Y., & Graves, D. T. (2014) · BioMed Research International · doi:10.1155/2014/925350 · Cited by 419 · see citing works

PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment

Zotano, Á. G., Mayer, I. A., & Arteaga, C. L. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9637-x · Cited by 419 · see citing works

Synthetic Oleanane Triterpenoids: Multifunctional Drugs with a Broad Range of Applications for Prevention and Treatment of Chronic Disease

Liby, K. T., & Sporn, M. B. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004846 · Cited by 410 · see citing works

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

Pérez‐Galán, P., Dreyling, M. H., & Wiestner, A. U. (2010) · Blood · doi:10.1182/blood-2010-04-189977 · Cited by 394 · see citing works

Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells

Muranen, T. E., Selfors, L. M., Worster, D. T., Iwanicki, M., Song, L., Morales, F. C., Gao, S., Mills, G. B., & Brugge, J. S. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.024 · Cited by 385 · see citing works

AMPK As a Metabolic Tumor Suppressor: Control of Metabolism and Cell Growth

Luo, Z., Zang, M., & Guo, W. (2010) · Future Oncology · doi:10.2217/fon.09.174 · Cited by 383 · see citing works

Targeting RTK Signaling Pathways in Cancer

Regad, T. (2015) · Cancers · doi:10.3390/cancers7030860 · Cited by 381 · see citing works

PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux

O’Donnell, J. S., Massi, D., Teng, M. W. L., & Mandalà, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.015 · Cited by 382 · see citing works

The PI3K/AKT Pathway and Renal Cell Carcinoma

Guo, H., Germán, P., Bai, S., Barnes, S., Guo, W., Qi, X., Lou, H., Liang, J., Jonasch, E. W., Mills, G. B., et al. (2015) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2015.03.003 · Cited by 373 · see citing works

Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer

Eser, S., Reiff, N., Messer, M., Seidler, B., Gottschalk, K., Dobler, M., Hieber, M., Arbeiter, A., Klein, S., Kong, B., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.023 · Cited by 360 · see citing works

NFAT proteins: emerging roles in cancer progression

Mancini, M., & Toker, A. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2735 · Cited by 371 · see citing works

PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia

Jansen, L. A., Mirzaa, G. M., Ishak, G. E., O'Roak, B. J., Hiatt, J. B., Roden, W. H., Gunter, S. A., Christian, S. L., Collins, S., Adams, C., et al. (2015) · Brain · doi:10.1093/brain/awv045 · Cited by 364 · see citing works

MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors

Turke, A. B., Song, Y., Costa, C., Cook, R., Arteaga, C. L., Asara, J. M., & Engelman, J. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3747 · Cited by 368 · see citing works

The molecular pathogenesis of head and neck squamous cell carcinoma

Rothenberg, S. M., & Ellisen, L. W. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59889 · Cited by 362 · see citing works

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Sarker, D., Ang, J. E., Baird, R. D., Kristeleit, R. S., Shah, K. J., Moreno, V., Clarke, P. A., Raynaud, F. I., Levy, G. G., Ware, J. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0947 · Cited by 361 · see citing works

The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein

Feng, Z., & Levine, A. J. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.03.004 · Cited by 359 · see citing works

microRNA Expression Patterns Reveal Differential Expression of Target Genes with Age

Noren Hooten, N., Abdelmohsen, K., Gorospe, M., Ejiogu, N., Zonderman, A. B., & Evans, M. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010724 · Cited by 357 · see citing works

Bcl-xL–inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets

Schoenwaelder, S. M., Jarman, K. E., Gardiner, E. E., Hua, M., Qiao, J., White, M. J., Josefsson, E. C., Alwis, I., Ono, A., Willcox, A., et al. (2011) · Blood · doi:10.1182/blood-2011-04-347849 · Cited by 351 · see citing works

Phosphoinositide signalling in cancer: beyond PI3K and PTEN

Bunney, T. D., & Katan, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2842 · Cited by 400 · see citing works

Ten things you should know about protein kinases: IUPHAR R eview 14

Fabbro, D., Cowan‐Jacob, S. W., & Möbitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 350 · see citing works

Advances in covalent kinase inhibitors

Abdeldayem, A., Raouf, Y. S., Constantinescu, S. N., Moriggl, R., & Gunning, P. T. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00720b · Cited by 332 · see citing works

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in <i>PIK3CA</i> -Mutant Breast Cancer

Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005747 · Cited by 332 · see citing works

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

Jankú, F., Tsimberidou, A. M., Garrido‐Laguna, I., Wang, X., Luthra, R., Hong, D. S., Naing, A., Falchook, G. S., Moroney, J. W., Piha-Paul, S. A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0994 · Cited by 331 · see citing works

AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas

Elkabets, M., Pazarentzos, E., Juric, D., Sheng, Q., Pelossof, R. A., Brook, S., Benzaken, A. O., Rodon, J., Morse, N., Yan, J. J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.010 · Cited by 325 · see citing works

Therapeutic Strategies for Targeting Ras Proteins

Gysin, S., Salt, M. B., Young, A. E., & McCormick, F. (2011) · Genes & Cancer · doi:10.1177/1947601911412376 · Cited by 321 · see citing works

The Role of Curcumin in Cancer Treatment

Zoi, V., Galani, V., Lianos, G. D., Voulgaris, S., Kyritsis, A. P., & Alexiou, G. Α. (2021) · Biomedicines · doi:10.3390/biomedicines9091086 · Cited by 335 · see citing works

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer

Mayer, I. A., Abramson, V. G., Formisano, L., Balko, J. M., Estrada, M. V., Sanders, M. E., Juric, D., Solit, D. B., Berger, M. F., Won, H. H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0134 · Cited by 320 · see citing works

Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer

Gil, E. M. C. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.03.004 · Cited by 315 · see citing works

Extracellular vesicles including exosomes are mediators of signal transduction: are they protective or pathogenic?

Gangoda, L., Boukouris, S., Liem, M., Kalra, H., & Mathivanan, S. (2015) · PROTEOMICS · doi:10.1002/pmic.201400234 · Cited by 301 · see citing works

Role of Phospholipids in Endocytosis, Phagocytosis, and Macropinocytosis

Bohdanowicz, M., & Grinstein, S. (2013) · Physiological Reviews · doi:10.1152/physrev.00002.2012 · Cited by 306 · see citing works

Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?

Tanaka, S., Louis, D. N., Curry, W. T., Batchelor, T. T., & Dietrich, J. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.204 · Cited by 308 · see citing works

AKT Inhibition in Solid Tumors With AKT1 Mutations

Hyman, D. M., Smyth, L. M., Donoghue, M. T. A., Westin, S. N., Bedard, P. L., Dean, E. J., Bando, H., El-Khoueiry, A. B., Fidalgo, J. A. P., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0143 · Cited by 309 · see citing works

Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer

Hao, Y., Samuels, Y., Li, Q., Krokowski, D., Guan, B.-J., Wang, C., Jin, Z., Dong, B., Cao, B., Feng, X., et al. (2016) · Nature Communications · doi:10.1038/ncomms11971 · Cited by 290 · see citing works

Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia

Park, S., Chapuis, N., Tamburini, J., Bardet, V., Cornillet‐Lefèbvre, P., Willems, L., Green, A. S., Mayeux, P., Lacombe, C., & Bouscary, D. (2009) · Haematologica · doi:10.3324/haematol.2009.013797 · Cited by 308 · see citing works

PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials

Jankú, F., Wheler, J. J., Naing, A., Falchook, G. S., Hong, D. S., Stepanek, V. M. T., Fu, S., Piha-Paul, S. A., Lee, J. J., Luthra, R., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1726 · Cited by 300 · see citing works

Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics

Krakstad, C., & Chekenya, M. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-135 · Cited by 301 · see citing works

Bone Microenvironment and Osteosarcoma Metastasis

Yang, C., Tian, Y. E., Zhao, F., Chen, Z., Su, P., Li, Y., & Qian, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21196985 · Cited by 293 · see citing works

Tyrosine kinase gene rearrangements in epithelial malignancies

Shaw, A. T., Hsu, P. P., Awad, M. M., & Engelman, J. A. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3612 · Cited by 291 · see citing works

Targeting the phosphoinositide 3-kinase pathway in cancer

Liu, P., Cheng, H.-L. M., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,722 · see citing works

Targeting PI3K/Akt signal transduction for cancer therapy

He, Y., Sun, M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,996 · see citing works

Molecular targeting: PI3 kinase pathway

Dancey, J. E. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh932 · Cited by 54 · see citing works

Akt inhibitors in cancer therapy

Alam, M., Ali, S., & Hassan, M. I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91287-7.00006-5 · Cited by 5 · see citing works

Targeting the PI3K pathway in cancer: are we making headway?

Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033 · see citing works